Detailed overview on rare malignant ovarian tumors.


Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 26 11 2019
revised: 29 12 2019
accepted: 13 01 2020
pubmed: 3 3 2020
medline: 27 3 2020
entrez: 3 3 2020
Statut: ppublish

Résumé

The group of rare malignant ovarian tumors includes the group of germ cell tumors, sex cords stromal ovarian tumors, small cell carcinoma, malignant Brenner tumors, rare epithelial tumors such as mucinous carcinoma, clear cell carcinoma, or low-grade serous carcinoma, as well as ovarian carcinosarcoma. Together they comprise about 10% of all ovarian tumors. Due to their low prevalence and their heterogeneity, data and treatment recommendations are limited. Even though all ovarian tumors are staged according to the FIGO staging of epithelial ovarian tumors, treatment differs especially in germ cell tumors and sex cords stromal ovarian tumors. Non-epithelial ovarian tumors can arise from a variety of ovarian precursor cells such as germ cells, granulosa cells, theca cells, or stromal fibroblasts. As can be expected already due to their divergent precursor lesions, these malignancies are substantially different but united by their rarity. This overview article gives a comprehensive summary on the pathology and clinical presentation, as well as therapy recommendations of a selection of those rare ovarian tumors, based on the latest national guidelines and related important publications.

Identifiants

pubmed: 32115180
pii: S0007-4551(20)30080-1
doi: 10.1016/j.bulcan.2020.01.011
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-390

Informations de copyright

Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Stefanie Aust (S)

Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna, Austria.

Lauriane Eberst (L)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Olivier Tredan (O)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Christine Rousset-Jablonski (C)

Department of Surgery, centre Léon-Bérard, Lyon, France.

Isabelle Treilleux (I)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Pierre Méeus (P)

Department of Surgery, centre Léon-Bérard, Lyon, France.

Nicolas Chopin (N)

Department of Surgery, centre Léon-Bérard, Lyon, France.

Fred Beurrier (F)

Department of Surgery, centre Léon-Bérard, Lyon, France.

Amandine Charreton (A)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Daval Véronique (D)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Amina Hallouz (A)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Agnès Coulon (A)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Alexis Ricoeur (A)

Department of Interventional Radiology, centre Léon-Bérard, Lyon, France.

Charles Mastier (C)

Department of Interventional Radiology, centre Léon-Bérard, Lyon, France.

Amine Bouhamama (A)

Department of Interventional Radiology, centre Léon-Bérard, Lyon, France.

Séverine Racadot (S)

Department of Radiotherapy, centre Léon-Bérard, Lyon, France.

Mojgan Devouassoux-Shisheboran (M)

Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.

Véronique Haddad (V)

Department of Medical Oncology, centre Léon-Bérard, Lyon, France.

Isabelle Ray-Coquard (I)

Department of Medical Oncology, centre Léon-Bérard, University Claude Bernard (UCBL Lyon1), Lyon, France. Electronic address: isabelle.ray-coquard@lyon.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH